Abstract
INTRODUCTION:Immune checkpoint inhibitor-mediated colitis (IMC) is commonly managed with steroids and biologics. We evaluated the efficacy of ustekinumab (UST) in treating IMC refractory to steroids plus infliximab and/or vedolizumab.RESULTS:Nineteen patients were treated with UST for IMC refractory to steroids plus infliximab (57.9%) and/or vedolizumab (94.7%). Most of them had grade ≥3 diarrhea (84.2%), and colitis with ulceration was present in 42.1%. Thirteen patients (68.4%) attained clinical remission with UST, and mean fecal calprotectin levels dropped significantly after treatment (629 ± 101.5 mcg/mg to 92.0 ± 21.7 mcg/mg, P = 0.0004).DISCUSSION:UST is a promising therapy for the treatment of refractory IMC.
Original language | English (US) |
---|---|
Pages (from-to) | 1679-1683 |
Number of pages | 5 |
Journal | American Journal of Gastroenterology |
Volume | 118 |
Issue number | 9 |
DOIs | |
State | Published - Sep 1 2023 |
Externally published | Yes |
Keywords
- cancer
- immune checkpoint inhibitor
- immune-mediated colitis
- refractory
- toxicity
- ustekinumab
ASJC Scopus subject areas
- Hepatology
- Gastroenterology